StockData
Cytek Biosciences, Inc. logo

Cytek Biosciences, Inc. (CTKB) company profile

CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/309% below fair value
$5.70+0.07 (+1.24%)

Close on Nov 17, 2026Market cap $740.91MP/E –Yield –

About Cytek Biosciences

Laboratory Analytical Instruments, SIC 3826

Cytek develops and sells cell analysis instruments, reagents, software, and services for biomedical research and clinical diagnostics. Its core products include full spectrum flow cytometers and cell sorters under the Aurora and Northern Lights brands, as well as conventional and imaging systems under the Amnis and Guava lines. The company also provides automated sample loaders, antibody cocktail preparation systems, reagent kits, and analysis software such as SpectroFlo and Cytek Cloud. Customers include pharmaceutical and biotechnology companies, contract research organizations, academic and governmental research institutions, and clinical laboratories.

Headquartered in Fremont, California, the company maintains manufacturing operations there as well as in San Diego, Seattle, Wuxi, and Singapore. Cytek employs more than 700 people, including over 270 commercial staff and more than 150 research and development personnel. It sells products globally through direct sales forces in North America, Europe, and Asia-Pacific, alongside distributor networks serving Latin America and the Middle East.

Summary of the business section of Cytek Biosciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Cytek Biosciences, Inc.
Founded
2014
Headquarters
Fremont, CA
Address
47215 Lakeview Boulevard 94538
Phone
(877) 922-9835
Employees
702, Dec 31, 2025
Industry
Laboratory Analytical Instruments
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, San Jose, California

Stock & identifiers

Ticker
CTKB
Exchange
Nasdaq
IPO date
Jul 23, 2021
Shares outstanding
130M, Jul 31, 2026
Public float
$393.00M, Jun 30, 2025
Filer category
Accelerated filer
SEC CIK
1831915
CUSIP
23285D109
ISIN
US23285D1090
FIGI
BBG00D36Q0Z7
Share class FIGI
BBG00D36Q103
LEI
549300K2J28BOC6FBO89
EIN
47-2547526

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Ming YanCHIEF TECHNOLOGY OFFICER, Director4,821,870
Wenbin JiangPRESIDENT AND CEO, Director8,248,585
Ilan FeuchtwangChief Legal Officer, Secretary–
William D. McCombeChief Financial Officer115,386
Valerie BarnettCHIEF LEGAL OFFICER139,315
Philippe BusqueSVP, GLOBAL SALES AND SERVICES36,711
Allen PoirsonSVP BUS. AND CORP. DEV.59,981
Richard ChinDirector28,499
Michael HolderDirector62,875
Glenn P. MuirDirector3,086
Jack BallDirector86,678
Deborah J. NeffDirector59,679
Vera ImperDirector59,679
Don M. HardisonDirector15,706

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$5.12M$3.64M$1.78M$27$114
FY2024$6.08M$4.40M$1.68M$35$85
FY2023$4.94M$3.72M$2.04M$49$86
FY2022$3.91M$1.93M$1.45M$54$82
FY2021$4.82M-$130.47K$2.59M$87$91

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Wenbin Jiang
Chief Executive Officer and President
$620.00K$2.00M$2.00M$485.21K$14.85K$5.12M-16%
William McCombe
Chief Financial Officer
$450.00K$900.00K$900.00K$210.98K–$2.46M+46%
Ming Yan
Chief Technology Officer
$425.00K$425.00K$425.00K$166.55K$15.87K$1.46M-21%
Valerie Barnett
Chief Legal Officer and Corporate Secretary
$475.00K$750.00K$750.00K$186.05K$13.89K$2.17M-10%
Philippe Busque
Senior Vice President, Global Sales and Services
$375.00K$250.00K$250.00K$146.73K–$1.02M+2%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 23, 2021
Offer price
$17.00
Securities offered
14,564,635
Gross proceeds
$247.60M
Exchange
Nasdaq
First trading day
Jul 23, 2021
First-day close
$18.76+10.4%
Lock-up ends (est.)
Jan 19, 2022

“The initial public offering price is $17.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 702 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?